|Articles|November 11, 2007
Highlights from Day 2 of the AAO Congress
New roles for the femtosecond discussed. Subretinal implant disappoints. Genentech defends its actions relating to Avastin decision. Glaucoma pipeline looks very healthy, and much more.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement












































